New Iron Deficiency Anemia Treatments 2021
Last updated: 15 March 2022
What is Iron Deficiency Anemia?
Iron deficiency is a state where the body lacks iron. It is the most common nutritional disorder in the world. Iron has a vital function in the body: it carries oxygen from the lungs to tissues. When this deficiency is not resolved, it leads to iron deficiency anemia. This is a common type of anemia - a disorder in which the blood lacks healthy red blood cells. Without enough iron, the body cannot produce hemoglobin - a substance in red blood cells that actually carries oxygen.
What are Iron Deficiency symptoms?
Iron deficiency anemia symptoms include:
- Extreme fatigue
- Pale skin
- Chest pain, fast heartbeat or shortness of breath
- Headache, dizziness or lightheadedness
- Cold hands and feet
- Inflammation or soreness of your tongue
- Brittle nails
- Unusual cravings for non-nutritive substances, such as ice, dirt or starch
- Poor appetite, especially in infants and children with iron deficiency anemia
Treatment of Iron Deficiency
To treat iron deficiency anemia, iron supplements may be recommended. If necessary, the underlying cause of your iron deficiency will also be treated.
Iron supplements can be taken to replenish the iron stores in the body. These supplements may be taken for several months or longer to replenish your iron reserves.
What are new Iron Deficiency treatments?
There are several approved Iron Deficiency treatments. Here are some of them:
Feraccru (ferric maltol)
Feraccru (ferric maltol) is a non-salt based oral iron replacement product indicated for the treatment of adults with low iron stores (iron deficiency) with or without anemia.
Feraccru (ferric maltol) was approved for the treatment of iron deficiency with or without anemia in adult patients by:
- The European Medicines Agency (EMA), EU, on February 18, 2016
- Swissmed, Switzerland, on April 24, 2019
- The Food and Drug Administration (FDA), USA, on July 26, 2019 under the brand name Feraccru (ferric maltol).
Evrenzo (roxadustat) is a medication used for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis patients.
Evrenzo (roxadustat) was approved for treatment of anemia in CKD patients dependent on dialysis by:
- The Pharmaceuticals and Medical Devices Agency (PMDA), Japan on September 20, 2019.
Evrenzo is approved in various other countries, including China, Chile and South Korea. It is under regulatory review in other regions, including in Europe, where it has recently received a positive CHMP opinion.
Reblozyl (luspatercept) is an interleukin-23 (IL-23) inhibitor used to treat anaemia that requires regular blood transfusions in adults with:
- Beta thalassemia
- Myelodysplastic syndromes
Reblozyl (luspatercept) was approved by:
- The Food and Drug Administration (FDA), USA, to treat anemia in adults with:
- beta thalassemia on November 8, 2019.
- myelodysplastic syndromes (MDS) on April 3, 2020.
- The European Medicines Agency (EMA), to treat anemia in adults with:
- beta thalassemia on June 26, 2020.
- myelodysplastic syndromes (MDS) on June 26, 2020.
- Health Canada to treat anemia in adults with beta thalassemia on September 29, 2020.
If you are trying to access new drugs for Iron Deficiency that are approved outside of your country of residence, we might be able to help you access it with the support of your treating doctor. You can read more about the medicines we can help you and your doctor access and about their price below:
Why access and buy Iron Deficiency Anemia treatments with TheSocialMedwork?
TheSocialMedwork is registered in The Hague with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM) and as an international pharmacy (registration number 16258 G). We have helped patients from over 85 countries to access thousands of medicines that are not yet approved in their home country, including patients suffering from Psoriatic Arthritis. With a prescription from your treating doctor, you can count on our expert team to safely and legally guide you to access Psoriatic Arthritis medicines in your country. If you or someone you know are looking to access a medicine that is not yet approved where you live, we will support you. Contact us for more information.
- Reblozyl (luspatercept)
- FDA Reblozyl
- Evrenzo (roxadustat)
- FDA Evrenzo
- Feraccru (ferric maltol)
- EMA Feraccru
Disclaimer: This article is not meant to influence or impact the care provided by your treating physician. Please do not make changes to your treatment without first consulting your healthcare provider. This article is not intended to diagnose or treat illness or to influence treatment options. TheSocialMedwork is as diligent as possible in compiling and updating the information on this page. However, TheSocialMedwork does not guarantee the correctness and completeness of the information provided on this page.